Pelthos Therapeutics Inc. (PTHS) reported Q3 result
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts PTHS Hot Sheet
Join SI Premium – FREE
Pelthos Therapeutics Inc. (NYSE: PTHS) reported Q3 EPS of ($5.30). Revenue for the quarter came in at $7.41 million.
For earnings history and earnings-related data on Pelthos Therapeutics Inc. (PTHS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura flags this tech pocket as 'portfolio shelter' from AI spending pressure
- CF Industries (CF) PT Lowered to $129 at Freedom Broker
- SkyAI expands tender offer to include all warrants, extends deadline
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
